Interview with Cornelia Yzer , CEO, VFA
2007 was a turning point for the German Pharmaceutical Industry as the Healthcare Reform from 2007 took place and the Special SHI enhancement Act entered into force. Two years down…
Address: Scheurlstraße 21 ,D-90478 Nürnberg Postbox 440138
Tel: +49 (0) 911 946469-0
Founded in 1998 by Daniel M. Perlman, RPS implemented its business plan to build the industry’s first Pharmaceutical Resource Organization model. The RPS plan was dedicated to achieving the goal of providing the biopharmaceutical industry with an alternative to traditional outsourcing models by offering customized, integrated solutions that addressed these fundamental industry challenges.The European growth of RPS allows clients to utilize the market leading integrated clinical solutions and enhanced full-service capabilities of RPS to develop clinical products beyond the Americas and into Europe for greater value generation across a global R&D pipeline. RPS recently acquired three CROs in Europe: in Germany, France and Spain. RPS entered the German market in December 2008, when they acquired Imerem GmbH. RPS has acquired Imerem’s specialist knowledge in major indications of clinical indications: CNS (neurology and psychiatry), oncology (solid, hematological tumors), transplantation, pain, dermatology. We are highly experienced in studies with phytomedicines and complementary medicinal treatments, medicinal products, and large-scale post-marketing surveillance studies. Imerem was in particular the world-wide leading CRO in research in the “Restless Legs Syndrome.”Executive Vice President of Clinical Operations in Europe and CEO of RPS Germany is Dr. Ralf Kohnen, former founder of Imerem GmbH.
2007 was a turning point for the German Pharmaceutical Industry as the Healthcare Reform from 2007 took place and the Special SHI enhancement Act entered into force. Two years down…
What role does the German Pharmaceutical Industry Association (BPI) play for the German pharmaceutical industry? BPI is the oldest industry association of the German pharmaceutical industry, dating back to 1951.…
Next year Baxter will accomplish its 50th anniversary in Germany. In the context of its celebration, what would you highlight as the main achievements of the company especially since you…
In the last twenty years, Germany has experienced nearly twenty health care reforms. In your opinion, what have been the main reasons for so many changes? The main reason behind…
Celgene is very new in the German market. What would you say have been the main achievements of Celgene Germany since its establishment in 2006? Celgene Germany started as a…
Could you briefly present the Association of German Biotechnology Companies (VBU) and DECHEMA e.V. to our readers and describe their importance to the German biotechnology industry? VBU is a non…
Hospira, which was spun-off from Abbott Laboratories in 2004, is a global specialty pharmaceutical and medication delivery company driven by its vision of Advancing Wellness™. Bringing proven leadership and experience,…
How challenging is for you as General Manager of Nycomed Germany to lead the number one subsidiary of the Nycomed Group and what would you highlight as the key milestones…
The acquisition of IVAX in 2006 was decisive to establish Teva as the number one generic producer worldwide and further consolidate the company in the German market; and this process…
Astellas has been present in the German market for almost two decades through Yamanouchi and Fujisawa. But since 2005 it gained a new identity thanks to the merger of the…
Cytonet is today Germany’s largest cell therapy enterprise. However, it went through many transformations since its spin-off from Roche Diagnostics in 2000. Could you briefly introduce the company to our…
The German Pharmaceutical Industry is not only known for its cutting-edge R&D and production base but also for having a high penetration of generics. In your opinion, what role do…
See our Cookie Privacy Policy Here